Abstracts tagged "Infection"

Abstract Number: 0207 • ACR Convergence 2023
Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos¹, Fadi Shehadeh², Markos Kalligeros¹ and Eleftherios Mylonakis³, ¹Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI, ²Houston Methodist Research Institute, Houston, TX, ³Department of Medicine, Houston Methodist Hospital, Houston, TX
Background/Purpose: Available immunosuppressive treatments for autoimmune inflammatory rheumatic diseases (AIRD) might increase the risk for opportunistic infections, such as Pneumocystis jirovecii pneumonia (PJP). Prophylactic trimethoprim-sulfamethoxazole…
Abstract Number: 0752 • ACR Convergence 2023
Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic DMARD: Gaps in Coverage Overall and Among JAKi Initiators
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA
Background/Purpose: Screening for latent tuberculosis (TB) is recommended prior to starting biologics or targeted synthetic DMARDs (b/tsDMARDs). With a growing number of these drugs available…
Abstract Number: 1500 • ACR Convergence 2023
Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies
Saira Sheikh¹, Kevin Withrop², Jinoos Yazdany³, Sandra Navarra⁴, Tatsuya Atsuma⁵, Paula Curtis⁶, Jose Miyar Olaiz⁷, Christine Henning⁸, Roger A. Levy⁹, William Stohl¹⁰ and Daniel Wallace¹¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ⁶GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁷GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁹GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹⁰University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with SLE have a high risk of infections, which remains a common cause of mortality in this population.1 This infection risk can result…
Abstract Number: 2050 • ACR Convergence 2023
Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey
Randal De Souza¹, Merav Heshin Bekenstein², Beth Rutstein³, Maria Schletzbaum⁴, Nora Singer⁵, Melanie Kohlheim⁶, vincent del gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock¹⁰, Rebecca Sadun¹¹, Monica Ardura¹, Vidya Sivaraman¹ and For The CARRA Registry Investgators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Dana Children's Hospital of Tel Aviv Medical Center, Tel Aviv, Israel, ³Division of Rheumatology at Children's Hospital of Philadelphia, Philadelphia, PA, ⁴St. Louis Children’s Hospital / Washington University in St. Louis, Middleton, WI, ⁵The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Self, Granville, OH, ⁷CARRA, Inc, Washington, DC, ⁸Nationwide Children's Hospital, Hilliard, OH, ⁹Ohio State University, Columbus, OH, ¹⁰Dept. of Biomedical Informatics, Columbus, OH, ¹¹Duke University, Durham, NC
Background/Purpose: Immunocompromised children (ICC), including children with rheumatic diseases receiving immunosuppressive therapies (IST) are at increased risk of morbidity from vaccine-preventable infections. The 2022 American…
Abstract Number: 2377 • ACR Convergence 2023
The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis
Sebastian Sattui¹, Xiaoqing Fu², Claire Cook², Shruthi Srivatsan², Yuqing Zhang² and Zachary Wallace³, ¹University of Pittsburgh, Pittsburgh, PA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Older adults with ANCA-associated vasculitis (AAV) have distinct clinical presentations and outcomes when compared to younger adults. Despite a high incidence of AAV in…
Abstract Number: 0208 • ACR Convergence 2023
Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System
Angela Bobak¹, Emely Pimentel¹, Jordan Jackson², Celia Gray³, Hema Srinivasan³, Andrea Berger³ and David Bulbin³, ¹Geisinger Medical Center Internal Medicine Residency, Danville, PA, ²Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, ³Geisinger Health System, Danville, PA
Background/Purpose: PJP is an opportunistic fungus causing significant morbidity and mortality in immunocompromised patients. Guidelines describe PJP PPX indications among non-HIV infected individuals with cancer…
Abstract Number: 0848 • ACR Convergence 2023
Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients
Kishan Majithiya¹, Komal Singh¹, Pankti Mehta², Chengappa Kavadichanda³, seema Sharma¹, Able Lawrence¹ and Amita Aggarwal¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²King George's Medical University, Mumbai, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Disease flare and infections are the major causes of fever in a patient with SLE. It is vital to differentiate between these two as…
Abstract Number: 1529 • ACR Convergence 2023
Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients
Silvia Bosello¹, enrico De Lorenzis¹, lucrezia verardi¹, gerlando Natalello¹, pier giacomo Cerasuolo¹, Stefano Di Donato², Greta Pellegrino³, Giacomo De Luca⁴, Corrado Campochiaro⁵, Gemma Lepri⁶, Laura Cometi⁷, Fabio Cacciapaglia⁸, Giuseppe Armetano⁹, Marco De Pinto¹⁰, Francesca Motta¹¹, Maria De Santis¹¹, Dilia Giuggioli¹², Nicoletta Del Papa⁹, Florenzo Iannone¹³, Serena Guiducci⁷, valeria Riccieri¹⁴, Maria Antonietta D'Agostino¹ and Francesco Del Galdo², ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³Department of Rheumatology, La Sapienza University of Rome, Rome, Italy, ⁴Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy, ⁵IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ⁶Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, ⁷University of Florence, Unit of Rheumatology Azienda Ospedaliera Careggi, Florence, Italy, ⁸Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁹Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy, ¹⁰Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Modena, Modena, Italy, ¹¹Reumatologia e Immunologia Clinica, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, Milan, Italy, ¹²Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, ¹³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁴Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy
Background/Purpose: Mycophenolate mofetil (MMF) is a first-line immunosuppressant treatment for systemic sclerosis (SSc), particularly for patients with interstitial lung disease (ILD) and diffuse skin involvement.…
Abstract Number: 2055 • ACR Convergence 2023
A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
Racheal Githumbi¹, Susan Kuhn¹, Carla Osiowy², Jennifer DeBruyn¹, Marvin Fritzler¹, Nicole Johnson¹, Otto G Vanderkooi¹ and Heinrike Schmeling¹, ¹University of Calgary, Calgary, AB, Canada, ²National Microbiology Laboratory, Public Health Agency of Canada, Winnepig, MB, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) and Crohn's disease (CD) are now controlled using immunosuppressive medications. However, disease control comes at the risk of increased infection.…
Abstract Number: 2387 • ACR Convergence 2023
Large Vessel Involvement and the Risk of Severe Infections in Patients with Giant Cell Arteritis – a Population-based Study
Nazanin Naderi¹, Aladdin Mohammad², Karin Wadström³, Ulf Bergström³ and Carl Turesson³, ¹Lund University, Kristiandstad, Sweden, ²Lund University, Lund, Sweden, ³Lund University, Malmö, Sweden
Background/Purpose: Manifestations of giant cell arteritis (GCA) include large vessel involvement (LVI) of the aorta and its branches. Aortic aneuryms are more common compared to…
Abstract Number: 0209 • ACR Convergence 2023
Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
Hilde Ørbo¹, Ingrid Jyssum¹, Anne Therese Tveter¹, Ingrid Christensen¹, Joseph Sexton¹, Kristin Hammersbøen Bjørlykke², Grete B. Kro³, Tore Kvien¹, Gunnveig Grødeland⁴, Ludvig A. Munthe⁵, Siri Mjaaland⁶, John Torgils Vaage⁵, Espen Haavardsholm¹, Kristin Kaasen Jørgensen², Sella Provan⁷, Silje Watterdal Syversen¹ and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁵Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁶Norwegian Institute of Public Health, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…
Abstract Number: 0886 • ACR Convergence 2023
Neonatal Roseolovirus Infection Predisposes to Development of Lupus-like Disease After TLR7 Stimulation
Tarin Bigley¹, Eden Xue¹, Lifei Zhu¹, Li-ping Yang¹ and wayne Yokoyama², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University School of Medicine, St. Louis, MO
Background/Purpose: Viral infections have been implicated as major factors in autoimmune disease but demonstrating causality is often challenging. We found that neonatal infection with a…
Abstract Number: 1544 • ACR Convergence 2023
Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis
Kai Zhao¹, J. Antonio Avina-Zubieta², Hui Xie³, Natasha Dehghan⁴ and John Esdaile², ¹Arthritis Research Canada, Coquitlam, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Simon Fraser University, Richmond, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of multisystem inflammatory diseases. One of the most serious and common side-effects of GC and…
Abstract Number: 2102 • ACR Convergence 2023
Is This Prosthetic Joint Infected or Flaring?
Susan Goodman, Insa Mannstadt, Kathleen Tam, Alejandro Kochen, Lorien Shakib, Peter Sculco, Mark Figgie, Alberto Carli, Andy Miller, Linda Russell, Allina Nocon and Laura Donlin, Hospital for Special Surgery, New York, NY
Background/Purpose: Diagnosis of a periprosthetic joint infection (PJI) in a patient with inflammatory arthritis (IA) is challenging, as features of IA flares can mimic an…
Abstract Number: 2388 • ACR Convergence 2023
Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study
Nazanin Naderi¹, Aladdin Mohammad², Karin Wadström³, Ulf Bergström³ and Carl Turesson³, ¹Lund University, Kristiandstad, Sweden, ²Lund University, Lund, Sweden, ³Lund University, Malmö, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common type of vasculitis in adults aged 50 years or older. Although the substantial morbidity from infections…

« Previous Page
1
…
5
6
7
8
9
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].